4.7 Article

The novel GLP-1-gastrin dual agonist, ZP3022, increases ß-cell mass and prevents diabetes in db/db mice

期刊

DIABETES OBESITY & METABOLISM
卷 15, 期 1, 页码 62-71

出版社

WILEY
DOI: 10.1111/j.1463-1326.2012.01676.x

关键词

ss-cell; diabetes; dual agonist; gastrin; GLP-1; glucose control

资金

  1. Zealand Pharma A/S

向作者/读者索取更多资源

Aim Diabetes is characterized by beta-cell deficiency, and therefore restoration of beta-cell function has been suggested as a potential therapy. We hypothesized that a novel glucagon-like peptide-1 (GLP-1)-gastrin dual agonist, ZP3022, improves glycaemic control via improvement of beta-cell status in db/db mice. Methods Diabetic mice were studied following short- or long-term treatment with either the GLP-1-gastrin dual agonist or the commercially available GLP-1 agonists (exendin-4 and liraglutide). The effects on glycaemic control were addressed by repeated glucose tolerance tests and/or measurements of HbA1c levels, and pancreatic islet and beta-cell masses were determined by stereology. Results ZP3022 and the pure GLP-1 agonists improved glycaemic control after both short- and long-term treatment compared with vehicle. Interestingly, the effect was sustainable only in mice treated with ZP3022. Stereology data displayed a dose-dependent increase of beta-cell mass (p < 0.05) following treatment with ZP3022, whereas no significant effect of liraglutide was observed (beta-cell mass: vehicle 3.7 +/- 0.2?mg; liraglutide (30?nmol/kg) 3.4 +/- 0.5?mg; ZP3022 (30?nmol/kg) 4.3 +/- 0.4?mg and ZP3022 (100?nmol/kg) 5.2 +/- 0.4?mg). Conclusion The novel GLP-1-gastrin dual agonist, ZP3022, improved glycaemic control in db/db mice, and pancreatic islet and beta-cell mass increased significantly following treatment with ZP3022 compared with vehicle.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据